MA29085B1 - Agent prophylactique ou thérapeutique pour le traitement des troubles du sommeil - Google Patents

Agent prophylactique ou thérapeutique pour le traitement des troubles du sommeil

Info

Publication number
MA29085B1
MA29085B1 MA29970A MA29970A MA29085B1 MA 29085 B1 MA29085 B1 MA 29085B1 MA 29970 A MA29970 A MA 29970A MA 29970 A MA29970 A MA 29970A MA 29085 B1 MA29085 B1 MA 29085B1
Authority
MA
Morocco
Prior art keywords
prophylactic
treatment
therapeutic agent
sleep disorders
sleep
Prior art date
Application number
MA29970A
Other languages
English (en)
Inventor
Keisuke Hirai
Masaomi Miyamoto
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36587809&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA29085(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of MA29085B1 publication Critical patent/MA29085B1/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/15Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA29970A 2004-12-13 2007-06-06 Agent prophylactique ou thérapeutique pour le traitement des troubles du sommeil MA29085B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2004359487 2004-12-13

Publications (1)

Publication Number Publication Date
MA29085B1 true MA29085B1 (fr) 2007-12-03

Family

ID=36587809

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29970A MA29085B1 (fr) 2004-12-13 2007-06-06 Agent prophylactique ou thérapeutique pour le traitement des troubles du sommeil

Country Status (17)

Country Link
US (1) US20080242682A1 (fr)
EP (1) EP1832286A4 (fr)
JP (1) JPWO2006064754A1 (fr)
KR (1) KR20070085973A (fr)
CN (1) CN101076328A (fr)
AR (1) AR052152A1 (fr)
AU (1) AU2005314935A1 (fr)
BR (1) BRPI0519016A2 (fr)
CA (1) CA2590838A1 (fr)
IL (1) IL183520A0 (fr)
MA (1) MA29085B1 (fr)
MX (1) MX2007006825A (fr)
NO (1) NO20073590L (fr)
PE (1) PE20060745A1 (fr)
RU (1) RU2007126638A (fr)
TW (1) TW200626137A (fr)
WO (1) WO2006064754A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0615357A2 (pt) * 2005-08-19 2011-05-17 Aventis Pharma Inc combinação de um agente hipnótico e r (+)-alfa-(2,3-dimetóxi-fenil)-1-[2-(4-fluorofenil)etil]-4-pi peridinometanol e aplicação terapêutica do mesmo
FR2889811B1 (fr) * 2005-08-19 2009-10-09 Sanofi Aventis Sa Association d'un agent hypnotique a duree d'action longue et d'un agent hypnotique a duree d'action courte, composition pharmaceutique la contenant et son application en therapeutique.
EP2236511A4 (fr) 2007-12-21 2011-04-13 Alla Chem Llc Ligands d'alpha-adrénorécepteurs, de récepteurs de dopamine, de l'histamine, d'imidazoline et de sérotonine ainsi que leurs procédés d'utilisation
US20120108669A1 (en) * 2008-11-13 2012-05-03 Sanofi-Aventis Method of treating sleep disorders using eplivanserin
EP2266554A1 (fr) * 2009-05-26 2010-12-29 Sanofi-Aventis Procédé de traitement des troubles du sommeil à l'aide de l'éplivanserine
EP2255726A1 (fr) * 2009-05-26 2010-12-01 Sanofi-Aventis Profil spectral de médicaments à amélioration SWS
EP2269600A1 (fr) * 2009-07-02 2011-01-05 Sanofi-Aventis Traitement des troubles du sommeil à l'aide de l'éplivanserine chez des patients atteints de bronchopneumopathie chronique obstructive
EP2727473A4 (fr) * 2011-06-28 2015-05-06 Vivozon Inc Combinaison de substances efficaces provoquant des effets synergiques d'un ciblage multiple, et son utilisation
WO2021205648A1 (fr) * 2020-04-10 2021-10-14 国立大学法人東海国立大学機構 Procédé objectif d'évaluation du sommeil pour un patient souffrant d'un trouble mental

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6034239A (en) * 1996-03-08 2000-03-07 Takeda Chemical Industries, Ltd. Tricyclic compounds, their production and use
WO1997032871A1 (fr) * 1996-03-08 1997-09-12 Takeda Chemical Industries, Ltd. Composes tricycliques, leur production et leur utilisation
JP4081161B2 (ja) * 1997-09-05 2008-04-23 武田薬品工業株式会社 光学活性化合物の製造法
DE69910795T2 (de) * 1998-06-09 2004-06-17 Takeda Chemical Industries, Ltd. Pharmazeutische kombination mit einer trizyclischen verbindung und mindestens einer von zolpidem, zopiclone und brotizolam, zur behandlung oder verhinderung von schlafstörungen
JP3509637B2 (ja) * 1998-06-09 2004-03-22 武田薬品工業株式会社 睡眠障害予防治療剤
US20030165566A1 (en) * 2002-01-10 2003-09-04 O'toole Edel Sedative non-benzodiazepine formulations
IL162860A0 (en) * 2002-01-10 2005-11-20 Biovail Lab Inc Sedative non-benzodiazepine formulations
IL149377A (en) * 2002-04-28 2012-10-31 Neurim Pharma 1991 Pharmaceutical formulation comprising melatonin for the potentiation of the effect of hypnotic compounds
US20050164987A1 (en) * 2003-12-24 2005-07-28 Barberich Timothy J. Melatonin combination therapy for improving sleep quality
FR2889811B1 (fr) * 2005-08-19 2009-10-09 Sanofi Aventis Sa Association d'un agent hypnotique a duree d'action longue et d'un agent hypnotique a duree d'action courte, composition pharmaceutique la contenant et son application en therapeutique.

Also Published As

Publication number Publication date
AR052152A1 (es) 2007-03-07
BRPI0519016A2 (pt) 2008-12-23
CN101076328A (zh) 2007-11-21
NO20073590L (no) 2007-09-03
IL183520A0 (en) 2007-09-20
MX2007006825A (es) 2007-07-25
WO2006064754A1 (fr) 2006-06-22
EP1832286A4 (fr) 2009-11-18
JPWO2006064754A1 (ja) 2008-06-12
PE20060745A1 (es) 2006-09-05
CA2590838A1 (fr) 2006-06-22
AU2005314935A1 (en) 2006-06-22
EP1832286A1 (fr) 2007-09-12
US20080242682A1 (en) 2008-10-02
RU2007126638A (ru) 2009-01-20
KR20070085973A (ko) 2007-08-27
TW200626137A (en) 2006-08-01

Similar Documents

Publication Publication Date Title
MA29085B1 (fr) Agent prophylactique ou thérapeutique pour le traitement des troubles du sommeil
FR19C1005I2 (fr) Nano-corps ameliores (tm) pour le traitement des troubles lies a l&#39;agregation
FR15C0046I2 (fr) Medicaments pour le traitement ou la prevention de maladies fibrotiques
FR13C0029I2 (fr) Compositions pour le traitement de troubles gastro-intestinaux
MA28791B1 (fr) Derives de piperazine convenant pour le traitement de troubles gastro-intestinaux
FR2882654B1 (fr) Utilisation de derives de la diosmetine pour le traitement et la prevention des pathologies thrombotiques
IL190295A0 (en) Combination therapy comprising substituted oxazolidinones for the prevention and treatment of cerebral circulatory disorders
FR13C0060I2 (fr) Omega-carboxyaryldiphenyluree fluoro-subtituee pour le traitement et la prevention de maladies et d&#39;etats pathologiques
MA28689B1 (fr) Derives de pyrrozolotriazine utiles pour le traitement des troubles et maladies hyperproliferatifs associes a l&#39;angiogenese
IL178730A0 (en) New pharmaceutical compositions for the treatment of sexual disorders ii
MA28481B1 (fr) Dérivés d&#39;imidazole pour le traitement de troubles neurodégénératifs
MA26992A1 (fr) Derives de phenethanolamine pour le traitement des maladies respiratoires
MA28555B1 (fr) Derives de morpholine substitues pour le traitement de troubles du systeme nerveux central
NO20053678D0 (no) Kombinasjonsterapi for behandling av immuninflammatoriske forstyrrelser
MA27027A1 (fr) Inhibiteur de pde4 et agent anticholinergique en association pour le traitement de maladies obstructives des voies aeriennes
FR2887141B1 (fr) Orthese compressive tricotee du membre inferieur pour le traitement de l&#39;insuffisance veineuse chronique
FR2854074B1 (fr) Utilisation de l&#39;ivermectine pour le traitement de desordres dermatologiques
FR2890562B1 (fr) Utilisation de l&#39;agomelatine pour l&#39;obtention de medicaments destines au traitement des troubles du sommeil chez le patient deprime
IL183656A0 (en) Indenyl derivatives and use thereof for the treatment of neurological disorders
MA28493B1 (fr) Sulfonamides destinés au traitement de troubles neurodégénératifs
NO20041833L (no) Heterocykliske forbindelser for anvendelse i behandlingen av forstyrrelser i urinveissystemet
IL193799A0 (en) New therapeutic combinations for the treatment or prevention of psycotic disorders
FR2906468B1 (fr) Utilisation de composes de la famille des avermectines pour le traitement de desordres dermatologiques
FR2908658B1 (fr) Composition pour la prevention et/ou le traitement des maladies associees a la surexpression du tnf et/ou de l&#39;il-12
EP1812009A4 (fr) Antagonistes des steroides gaba et leur utilisation dans le traitement des troubles du snc